Search
forLearn
5 / 801 resultslearn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn Cyproterone
a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor
learn Baicapil
learn Kopexil
Research
5 / 1000+ resultsresearch Hair loss in psychopharmacology.
Some psychiatric medications can cause hair loss, but stopping or reducing the dose usually reverses it.
research Inhibition of the pro-oxidant effects of benoxaprofen on poiymorpbonuclear leucocytes by retinol acetate in vitro
Retinol acetate can reduce the harmful effects of the drug benoxaprofen on white blood cells.
research PROGRESSIVE SLEEP APNOEAS RESPOND TO MEDROXYPROGESTERONE ACETATE
Medroxyprogesterone acetate improved sleep apnea symptoms in some obese patients.
research Antidepressant-like effect of fluoxetine may depend on translocator protein activity and pretest session duration in forced swimming test in mice
Fluoxetine's effectiveness as an antidepressant in mice depends on a specific protein activity and a 5-minute pretest.
research Drug-induced changes in hair growth
Some drugs can cause hair loss or growth, but hair usually returns to normal after stopping the drug.
Community Join
5 / 1000+ resultscommunity pyrilutamide solution progress log
A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.
community Pyrilutamide - your experience?
The conversation is about the lack of improvement in hair loss after using Pyrilutamide for 14 weeks, with the original poster unable to use Finasteride due to depression. Replies suggest that Pyrilutamide, like RU58841, may not work for everyone, and a more potent drug is being developed by Kintor.
community The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
community Kintor Phase 2 Results released KX-826 (pyrilutamide)
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.